Denali Therapeutics (DNLI) Depreciation & Amortization (CF) (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Depreciation & Amortization (CF) data on file, last reported at $2.8 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $2.8 million, up 22.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.7 million (up 47.27% YoY), and the FY2025 annual result was $11.2 million, up 43.68% from the prior year.
• Depreciation & Amortization (CF) retreated to $2.8 million in Q1 2026 per DNLI's latest filing, from $2.9 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $10.0 million in Q1 2023 and troughed at $1.8 million in Q3 2024.
• A 5-year average of $2.9 million and a median of $2.2 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) jumped 383.26% in 2023, then slumped 78.48% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $4.1 million in 2022, then tumbled by 47.01% to $2.2 million in 2023, then retreated by 14.88% to $1.9 million in 2024, then jumped by 55.59% to $2.9 million in 2025, then fell by 1.32% to $2.8 million in 2026.
• Business Quant data shows DNLI's Depreciation & Amortization (CF) at $2.8 million in Q1 2026, $2.9 million in Q4 2025, and $2.9 million in Q3 2025.